1. Home
  2. BIAF vs FBGL Comparison

BIAF vs FBGL Comparison

Compare BIAF & FBGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIAF
  • FBGL
  • Stock Information
  • Founded
  • BIAF 2014
  • FBGL 1996
  • Country
  • BIAF United States
  • FBGL Singapore
  • Employees
  • BIAF N/A
  • FBGL N/A
  • Industry
  • BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • FBGL Miscellaneous manufacturing industries
  • Sector
  • BIAF Health Care
  • FBGL Consumer Discretionary
  • Exchange
  • BIAF Nasdaq
  • FBGL Nasdaq
  • Market Cap
  • BIAF 12.2M
  • FBGL 12.4M
  • IPO Year
  • BIAF 2022
  • FBGL 2025
  • Fundamental
  • Price
  • BIAF $0.49
  • FBGL $0.74
  • Analyst Decision
  • BIAF Hold
  • FBGL
  • Analyst Count
  • BIAF 1
  • FBGL 0
  • Target Price
  • BIAF N/A
  • FBGL N/A
  • AVG Volume (30 Days)
  • BIAF 28.5M
  • FBGL 407.7K
  • Earning Date
  • BIAF 05-14-2025
  • FBGL 01-01-0001
  • Dividend Yield
  • BIAF N/A
  • FBGL N/A
  • EPS Growth
  • BIAF N/A
  • FBGL N/A
  • EPS
  • BIAF N/A
  • FBGL 0.04
  • Revenue
  • BIAF $9,362,022.00
  • FBGL $15,607,369.00
  • Revenue This Year
  • BIAF N/A
  • FBGL N/A
  • Revenue Next Year
  • BIAF $19.99
  • FBGL N/A
  • P/E Ratio
  • BIAF N/A
  • FBGL $16.99
  • Revenue Growth
  • BIAF 269.68
  • FBGL 25.78
  • 52 Week Low
  • BIAF $0.24
  • FBGL $0.44
  • 52 Week High
  • BIAF $3.16
  • FBGL $5.45
  • Technical
  • Relative Strength Index (RSI)
  • BIAF 48.21
  • FBGL N/A
  • Support Level
  • BIAF $0.46
  • FBGL N/A
  • Resistance Level
  • BIAF $0.58
  • FBGL N/A
  • Average True Range (ATR)
  • BIAF 0.11
  • FBGL 0.00
  • MACD
  • BIAF -0.01
  • FBGL 0.00
  • Stochastic Oscillator
  • BIAF 8.65
  • FBGL 0.00

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial and industrial building projects. As a green contractor focused on environmentally sound practices, It aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, lead lining, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts, sales of construction materials, and rendering of services.

Share on Social Networks: